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Abstract 
Introduction: Local delivery of antibiotics using bone cement as the delivery vehicle is an 
established method of managing implant-associated orthopedic infections. Various fillers have been 
added to cement to increase antibiotic elution, but they often do so at the expense of strength. This 
study evaluated the effect of adding a borate bioactive glass, previously shown to promote bone 
formation, on vancomycin elution from PMMA bone cement. 
Methods: Five cement composites were made: three loaded with borate bioactive glass along with 
0, 1, and 5 grams of vancomycin and two without any glass but with 1 and 5 grams vancomycin to 
serve as controls. The specimens were soaked in PBS. Eluate of vancomycin was collected every 24 
hours and analyzed by HPLC. Orthopedic-relevant mechanical properties of each composite were 
tested over time. 
Results: The addition of borate bioactive glass provided an increase in vancomycin release at Day 1 
and an increase in sustained vancomycin release throughout the treatment period. An 87.6% and 
21.1% increase in cumulative vancomycin release was seen for both 1g and 5g loading groups, 
respectively. Compressive strength of all composites remained above the weight-bearing threshold 
of 70 MPa throughout the duration of the study with the glass-containing composites showing 
comparable strength to their respective controls. 
Conclusion: The incorporation of borate bioactive glass into commercial PMMA bone cement can 
significantly increase the elution of vancomycin. The mechanical strength of the cement-glass 
composites remained above 70 MPa even after soaking for 8 weeks, suggesting their suitability for 
orthopedic weight-bearing applications. 
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Introduction 
Periprosthetic joint infections are considered one 
of the most serious complications following 
orthopedic procedures. Studies of the Medicare 
population between 1997 and 2006 found the risk of 
infection within the first two years following total 
joint replacement to be 1-2%.[1,2] Treatment often 
requires prolonged systemic and local delivery of 
antibiotics. Local antibiotic delivery is usually done 
by injection, sprinkling into the open wound, or 
delivery from an implanted device, the most common 
of which is bone cement. While it may not be the best 
drug delivery vehicle, bone cement is used by 
surgeons to deliver antibiotics because it is often 
already at the site of infection in the form of 
temporary spacers, bone void filler, or for implant 
anchorage.  
 The addition of antibiotics to bone cement was 
successfully introduced as a means to treat infection 
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around prosthetic joints in 1970.[3] Until 2003, when 
the first commercially available preloaded antibiotic 
bone cement became available, surgeons added 
antibiotics to the cement during mixing in the OR.[4] 
Given the limited variety of antibiotics preloaded 
within commercial bone cement, surgeons often add 
additional antibiotics or other antimicrobial 
components into bone cement in the OR. The 
aminoglycosides gentamicin and tobramycin are the 
most common antibiotics commercially preloaded 
into bone cement, while vancomycin is the most 
common antibiotic added to cement in the OR. 
 Poly(methyl methacrylate) (PMMA), one of the 
most widely used thermoplastic acrylics, has been 
used as a base for bone cement since the 1940s.[5] 
Although routinely used and recognized as an 
effective drug delivery vehicle, PMMA-based bone 
cement typically elutes merely a small fraction of the 
antimicrobials that are mixed into it, almost all of 
which is released during the first few days.[6] PMMA 
hardens to form an inherently impermeable, 
nonresorbable, hydrophobic, and low-porosity solid 
that is not optimal for the delivery of drugs. However, 
despite its hydrophobicity, PMMA and PMMA-based 
bone cement can still absorb up to as much as 2% 
water by weight.[7-9] This fluid absorption and 
exchange allows for some of the drug molecules to 
escape from the confines of the PMMA matrix, but 
primarily only those near the surface of the cement. 
One approach to increasing antibiotic delivery might 
be to simply increase the amount of antimicrobial 
mixed into the cement. However, drug incorporation 
into cement can be limited by the additive’s negative 
effect on the cement’s mechanical strength, 
workability, setting time, or other properties.[10,11] 
 Numerous techniques and additives have been 
evaluated as a means of increasing bone cement’s 
elution of antibiotics while subsequently trying to 
maintain the mechanical properties necessary for its 
use as a load-bearing cement. Increasing porosity or 
inhomogeneity of bone cement composites has been a 
primary goal. Mixing without vacuum or delaying the 
mixing until the cement has partially polymerized has 
been shown to promote increased elution of 
antibiotics.[12] A combination of additives can also be 
used to increase elution. Penner et al. showed that the 
addition of tobramycin and vancomycin together into 
PMMA as opposed to adding either alone increased 
the elution of both antibiotics from PMMA.[13] Other 
techniques for increasing elution have focused on 
adding various materials to function as porogens, 
such as polymers or bioactive glasses.[14] The 
addition of a bioresorbable filler to the bone cement 
creates the possibility of increasing cement porosity 
over time as the filler resorbs, leaving behind channels 
for drug escape. Xylitol and chitosan have been 
studied for their use as bioresorbable porogens within 
PMMA and have been shown to increase drug elution 
from the cement at the cost of decreased cement 
strength.[15,16] 
 Silicate and borate bioactive glasses are the most 
common bioactive glasses to be used in medicine.[17] 
The original silicate bioactive glass formulation, 
Bioglass 45S5, was first formulated in 1969 by Dr. 
Larry Hench and has since been studied 
extensively.[18,19] Silicate-free borate bioactive glass 
was introduced in 2005 as an alternative bioactive 
glass for cell-based bone tissue engineering 
scaffolds.[20,21] These bioactive glasses have several 
properties that make them potentially useful in bone 
healing and infection sites. First, they support local 
bone growth. As the bioactive glass particles dissolve 
in vivo, the ions released from the glass support 
osteogenic activity, promoting healing.[22,23] Second, 
once released, calcium and phosphate ions from the 
glass combine with local ions to form a 
hydroxyapatite (HA)-like layer on the material’s 
surface that has the ability to bond with hard and soft 
tissues, including bone.[24,25] Third, bioactive glasses 
can be antimicrobial themselves and have been shown 
to be bactericidal either alone or when doped with 
trace quantities of elements known to have 
antimicrobial effects such as silver, gallium, or 
iodine.[26-28] 
 Studies have suggested that bioactive glass may 
aid in local antibiotic delivery from cement as well as 
in bone regeneration.[26] A previous study by D. 
Arcos et al. investigated the addition of silicate 
bioactive glass to acrylic bone cement.[29] They found 
that this combination could be used to control 
antibiotic elution, and that the presence of bone 
cement and gentamicin did not affect the bioactive 
behavior of the glass. Compared to silicate-based 
bioactive glass, borate bioactive glasses degrade faster 
and convert more completely to an HA-like layer due 
to their lower chemical durability and higher aqueous 
solubility.[25,30] For this reason, borate bioactive 
glass may be a better candidate than silicate glass to 
increase antibiotic delivery from bone cement. 
 Given the potential advantages, this study 
sought to evaluate whether adding borate bioactive 
glass to PMMA bone cement would increase the rate 
of antibiotic elution while maintaining the cement’s 
mechanical strength. We hypothesized that 
PMMA-based bone cement with incorporated 
bioactive glass would increase the total elution of 
vancomycin for both low and high vancomycin loads 
and that the mechanical strength would not be 
reduced below the 70 MPa ISO standard.[31]  
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Methods 
Cement Composite Preparation 
The bone cement used was SmartSet MV 
(DePuy, Warsaw, IN, USA). The cement was sterile 
and used prior to its expiration date. Medical grade 
vancomycin • HCl powder was obtained from 
Fagron, Inc. through Sigma-Aldrich. 
Borate bioactive glass (13-93B3) was prepared at 
and obtained from Missouri University of Science and 
Technology (Dr. Mohamed Rahaman). 13-93B3 
(mol%: 6 Na2O, 7.9 K2O, 7.7 MgO, 22.1 CaO, 54.6 B2O3, 
1.7 P2O5) was prepared by mixing Na2CO3, K2CO3, 
MgCO3, CaCO3, NaH2PO4 • 2H2O, and H3BO3 (Fisher 
Scientific) together and heating the mixture to 1100°C 
for 1 hour inside a platinum crucible, which was then 
quenched between steel plates at room temperature 
(23 °C). The glass was crushed to a diameter of 5 µm 
by grinding 100g of glass frits for 150 seconds in a 
steel shatterbox (8500 Shatterbox, Spex SamplePrep 
LL, Metuchen, NJ). The glass was then ground for 90 
minutes in an attrition mill (Model 01-HD, Union 
Process, Akron, OH). Once dried, the glass was 
ground with a mortar and pestle and then sieved 
though a stainless steel sieve. Particle size analysis, 
performed using a Microtrac S3000 particle size 
analyzer, showed the glass had an average size of 5 
µm with a standard deviation of 3 µm. 
Five cement groups were prepared, each with 
different compositions (Table 1). For each group the 
dry cement component (40g) was mixed with a set 
amount of borate bioactive glass and/or vancomycin 
powder using a manual mixer without vacuum at the 
rate of 1 rotation per sec until uniform. The 20-mL 
liquid monomer component was then added and 
further mixed at 1 Hz for 90 seconds. 
Following mixing, the above groups were 
checked for the doughing stage every 15 seconds as 
per ASTM standard F451-16.[32] Once the doughing 
stage was achieved, they were then placed into a 
polytetrafluoroethylene (PTFE) mold, yielding 6 mm 
by 12 mm cylinders. The mold was placed into an 
incubator held at 37°C for one hour to allow cement 
curing. Afterwards, the cement cylinders were 
removed from the mold and inspected for significant 
defects. Defective cylinders were discarded. 
Elution Testing 
Ten specimens from each group were each 
placed separately into 15-mL polypropylene tubes to 
which 2.5 mL of phosphate-buffered saline (PBS, 
pH=7.4, Ricca Chemical, Arlington, TX) was added, 
allowing enough volume to cover the entirety of the 
specimens. The tubes were sealed and placed within 
an incubator at 37°C. Elution collection was 
performed every 24 hours and carried out for 2 weeks 
for V1 and BGV1. Elution collection was extended to 4 
weeks for V5 and BGV5. The residual PBS was 
discarded and replenished after each collection. The 
vancomycin concentration of each eluate was 
analyzed using a Shimadzu 10 series HPLC with a 
Hypersil GOLD C18 column (5 µm, 250 x 4.6 mm). 
Isocratic elution was performed with a mobile phase 
consisting of water—acetonitrile—100 mM 
ammonium acetate (composite ratio, 78/12/10 
v/v/v%), adjusted to a pH of 5.4.[33] Detection 
wavelength was set to 214nm. The mobile phase was 
prepared daily. Standard vancomycin calibration 
curves were prepared with each mobile phase 
preparation. The concentration of vancomycin was 
determined by recording elution peaks, baseline 
correction with control (BG), and matching the value 
to the corresponding standard curve. Analysis was 
performed using MATLAB (MathWorks, Natick, 
MA).  
Since a standard commercial bone cement kit 
containing 40g of powder and 18.88g of monomer was 
used as the basis for this study, the addition of the 
glass to groups BGV1 and BGV5 lowered the weight 
ratio of vancomycin in these groups relative to V1 and 
V5. To compensate for this difference in vancomycin 
content, a correction factor was applied to the groups 
containing bioactive glass and used when comparing 
relative elution (10.59% in BGV1 and 6.47% in BGV5). 
This correction factor was based on the measured 
average weight of the pellets in each group and the 
calculated amount of vancomycin in each pellet. The 
vancomycin in each pellet is equivalent to [(avg. wt. of 
pellet in group) x (vancomycin in batch)]/batch 
weight. This yielded a conservative correction factor 
for comparing elution from pellets having different 
vancomycin content due to the addition of glass.  
 
Table 1. The compositions of the antibiotic- and glass-loaded cement groups studied. 
Sample 
Group 
Vancomycin 
(g) 
Glass 
(g) 
SmartSet MV Powder 
(g) 
Liquid Component 
(g) 
Vancomycin Component 
(wt.%) 
Glass Component 
(wt.%) 
Specimen Avg. Mass 
(g) 
BG 0 10 40 18.88 0 14.5 0.4358 
V1 1 0 40 18.88 1.67 0 0.4182 
V5 5 0 40 18.88 7.83 0 0.4036 
BGV1 1 10 40 18.88 1.43 14.3 0.4413 
BGV5 5 10 40 18.88 6.77 13.5 0.4384 
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Compression Testing 
The compressive properties of samples from 
each group were determined using an MTS Mini 
Bionix 858 loadframe with MTS Series 793™ Control 
Software (MTS Systems Corporation, 14000 
Technology Drive, Eden Prairie, MN). Data was 
collected at 20 Hz. Five random samples from each 
group were tested in compression after having soaked 
at 37°C for 0, 1, 2, 3, 4, and 5 weeks for BG, V1, and 
BGV1 and for 0, 2, 4, 6, and 8 weeks for V5 and BGV5 
with daily change-out of PBS. Testing was done at a 
loading rate of 20 mm/min to either 40% strain or 
fracture, whichever occurred first. Fracture was 
considered to have occurred when the load fell to 
below 90% of its peak value. The compressive 
strength of the pellets was defined as the failure load 
divided by the cross-sectional area of the pellets. The 
failure load was taken as either the load at the 2.0% 
offset from the elastic section of the stress-strain 
curve, the ultimate yield load, or the load at fracture, 
whichever occurred first. Young’s modulus was 
defined as the slope of the elastic section of the 
material’s stress-strain curve. The ISO 5833 and ASTM 
F451 standards for the compressive strength of acrylic 
bone cement (minimum of 70 MPa) were used as a 
comparative threshold.[31,32] 
Statistical Analysis 
For daily elution, post-hoc unpaired t-tests were 
used to find significant intra-day differences between 
groups with equal variance, and Welch’s t-test was 
used for data sets with unequal variances. For total 
elution, univariate ANOVAs were used to test for 
significant effects of the groups’ compositions. The 
compressive strengths and Young’s moduli of the 
studied groups were also compared using unpaired 
t-tests for equal variances and Welch’s t-test for 
unequal variances. The variances of values were 
considered unequal if the larger variance was more 
than three times the smaller variance.  
Results 
Vancomycin Elution 
The daily elution profiles of both the 1g and 5g 
groups are shown below in Figure 1 and Figure 2, 
respectively. For the 1g groups, BGV1 showed 
significantly greater cumulative vancomycin elution 
(p<0.001). A significant difference was seen in elution 
vancomycin concentration at every day until Day 10 
(p<0.05). For the 5g groups, BGV5 again showed 
significantly greater cumulative elution of 
vancomycin compared to V5 (p<0.001). A significant 
difference was seen in elution vancomycin 
concentration for every day except D11, D12, D14, 
D16, D18, D20, D26, and D28 (p<0.05). At Day 1, 
BGV1 concentration was 76.48% greater than that of 
V1 (p<0.001) and BGV5 had a 17.42% greater 
concentration than V5 (p<0.001). The total mass of 
vancomycin released over the elution duration for all 
groups is compared in Figure 3. BGV1 released 
87.56% more vancomycin by mass than V1 over 14 
days. BGV5 released 20.76% and 21.10% more 
vancomycin by mass than V5 over the course of 14 
and 28 days, respectively. The cumulative release of 
vancomycin as a percentage of vancomycin release vs. 
vancomycin incorporated is shown in Figure 4. BGV1 
was able to release the greatest percentage of its 
loaded vancomycin. 
 
 
 
Figure 1. Vancomycin concentration of daily eluate for 1g groups (n=10). An asterisk (*) above a data point indicates a significant difference (p<0.05) between BGV1 and V1. 
Error bars indicate ± one standard deviation from the mean. 
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Figure 2. Vancomycin concentration of daily eluate for 5g groups (n=10) on a log scale. An asterisk (*) above a data point set indicates a significant difference (p<0.05) between 
BGV5 and V5. Error bars indicate ± one standard deviation from the mean. 
 
 
Figure 3. Average total elution of vancomycin over 14 days for all groups, and 28 days for V5 and BGV5. Error bars indicate ± one standard deviation from the mean (n=10). 
 
 
Figure 4. Cumulative average of vancomycin eluted from each group (n=10) as a percentage of vancomycin contained within each group over the treatment period. 
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Mechanical Characterization 
 The compressive strengths of V1, BG, and BGV1 
are shown in Figure 5. The compressive strengths of 
V5 and BGV5 are shown in Figure 6. Significant 
differences were noted for V1 and BGV1 at days 7 and 
21, for V1 and BG at days 21 and 28, and for BG and 
BGV1 at day 7. Throughout the duration, no group’s 
compressive strength fell below 70 MPa. All groups 
recorded their max strength at Day 0 with steady 
decline throughout the treatment period. Significant 
differences were noted between V5 and BGV5 at Day 
0, 42, and 56. Throughout the duration, neither 
group’s compressive strength fell below 70 MPa. Both 
groups had the highest compressive strength at Day 0, 
which then fell for throughout the treatment period. 
Separate single-factor ANOVAs were run for 1g and 
5g groups which revealed that both time and 
bioactive glass addition were found to significantly 
affect compressive strength (p<0.05).  
The Young’s modulus for the 1g groups and 5g 
groups are displayed in Figure 7 and Figure 8, 
respectively. Young’s modulus slowly decreased over 
time for both groups, similar to compressive strength. 
Significant differences between V5 and BGV5 were 
detected 14, 28, and 42 days after the beginning of 
soaking. Separate single-factor ANOVAs were run for 
1g and 5g groups which revealed that both time and 
bioactive glass addition were found to significantly 
affect Young’s modulus (p<0.05). 
Discussion 
An advantage of locally delivered antibiotics is 
that a higher concentration of drug can be achieved at 
the site of concern without the toxicity of orally or 
intravenously administered antibiotics.[34,35] A 
major concern associated with antibiotic-laden bone 
cement is the ability of pathogens to develop drug 
resistance upon sustained exposure to low local 
concentration of drug, specifically when below the 
Minimum Inhibitory Concentration (MIC).[36-38] By 
increasing the sustained release of a drug from bone 
cement, it becomes less likely a pathogen will be 
exposed to below MIC conditions before infection 
clearance. 
 
 
Figure 5. The compressive strengths of V1, BG, and BGV1 over time. An asterisk (*) over a bar represents a significant difference (p<0.05) between the groups (n=5) at the ends 
of the bar. Error bars represent ± one standard deviation. The dashed line indicates the 70 MPa threshold. 
 
Figure 6. The compressive strengths of V5 and BGV5 over time. An asterisk (*) above a time point represents a significant difference (p<0.05) between the groups (n=5) at that 
time duration. Error bars represent ± one standard deviation. The dashed line indicates the 70 MPa threshold. 
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Figure 7. The Young’s moduli of V1, BG, and BGV1 over time. An asterisk (*) over a bar represents a significant difference (p<0.05) between the groups (n=5) at the ends of 
the bar. Error bars represent ± one standard deviation. 
 
Figure 8. The Young’s moduli of V5 and BGV5 over time. An asterisk (*) above a time point represents a significant difference (p<0.05) between the groups (n=5) at that time 
duration. Error bars represent ± one standard deviation. 
 
Little is known about the role of a water soluble 
glass in aiding antibiotic elution from cement. It is 
believed that as the solution penetrates into the 
cement it comes into contact with the soluble glass. 
The dissolved glass solution moves towards areas of 
less concentration, creating larger pores and carrying 
along with it the antibiotic.[39,40] While inert fillers 
can improve antibiotic elution, bioactive fillers can 
serve further beneficial purposes within the context of 
the bone-cement-implant interface. As the bioactive 
glass dissolves, its components precipitate back onto 
the surface as calcium phosphate, which crystallizes 
into hydroxyapatite.[41]  
The addition of borate bioactive glass into bone 
cement functions as a water soluble porogen that 
allows for significant increases in vancomycin elution 
from the cement. Even with a modest glass loading 
percentage (13-15, wt.%), both groups loaded with 
either 1g or 5g of vancomycin outperformed their 
respective controls. The perceived mechanism lending 
to this increase in elution was mentioned earlier, 
being that the dissolved glass would allow for further 
fluid contact and exchange with the previously 
entrapped drug. Interestingly, when comparing the 
percentage of vancomycin eluted compared to the 
amount loaded into each group, BGV1 released nearly 
double that of all other groups. As the loading of 
vancomycin increases, diminishing returns are 
observed in terms of vancomycin release percentage.  
Concerns have been raised over the potential 
cytotoxicity of borate bioactive glass, and the 
inhibition of cellular growth by boron has been seen 
in some in vitro tests.[25,42] However, these same 
issues have not been seen in vivo, possibly due to the 
dynamic nature of the environment and the body’s 
ability to metabolize and transport boron ions away 
from the site before they can collect enough in areas to 
create cytotoxic concentrations.[42] Jia et al. 
performed an in vivo rabbit infection experiment in 
which they implanted borate bioactive glass loaded 
with teicoplanin at 10% w/w%. They found superior 
osteogenic and bone healing responses compared to 
that of calcium sulfate loaded with teicoplanin and 
reduced MRSA cultures compared to those treated 
intravenously.[43] 
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For all groups, the compressive strength was 
higher than the ASTM and ISO minimum standard of 
70 MPa, even after 35 and 56 days of soaking. When 
significantly different from BGV1 or BG, V1 had lower 
compressive strengths, revealing the reinforcing effect 
provided by the glass. BGV5 had a significantly 
higher compressive strength than V5 at Day 0 but 
slowly fell below V5 by Day 42 and 56 of soaking. This 
could be attributed to the increased mass loss from 
elution of both the drug and glass over a long period 
in aqueous solution. The moduli for all groups 
remained below an average of 2.5 GPa. This low 
moduli can help prevent stress shielding from a 
mismatch in bone and implant mechanical 
properties.[44] 
Three previous papers have been published on 
glass-antibiotic-PMMA composites.[29,45,46] None of 
these used borate bioactive glass or evaluated changes 
in composite strength over time after exposure to 
fluid. The primary focus of these studies appeared to 
be directed toward characterization and development 
of cement-filler composites for low strength 
applications, whereas we focused on maintenance of 
mechanical properties for load-bearing applications 
with a relatively low filler amount. 
Arcos et al. demonstrated gentamicin release 
from a silicate glass (SiO2-CaO-P2O5)/PMMA 
composite material but primarily investigated 
whether the presence of the antibiotic and PMMA had 
any substantial effect on the bioactivity of the 
glass.[29] Ragel et al. also characterized cement 
composites using the same bioactive glass as Arcos 
but with the addition of poly(L-lactic acid) 
(PLA).[45] As did Arcos, Ragel characterized the 
formation of HA onto the composite’s surface but did 
not measure material strength or compare the 
antibiotic elution achieved to any control or other 
composite. When compared to the results reported in 
the Arcos paper, they did seem to find a slightly 
higher elution rate with the addition of the PLA. Both 
papers reported a robust apatite-like formation on the 
surface of the composite material, demonstrating 
strong bioactivity despite the presence of the PMMA 
and antibiotic. It should be noted that the composites 
from both of these studies had relatively low 
percentages of PMMA by weight: Arcos 32 wt.%, 
Ragel 27 wt.%. From these low PMMA cement 
composites, they were able to deliver around 80% of 
the incorporated gentamicin over 48 hours. Neither of 
these studies made a comparison of antibiotic release 
rates between PMMA and the glass/PMMA 
composite to evaluate the beneficial effects on elution 
from glass addition. In our study, we did make a 
head-to-head comparison to controls and were able to 
demonstrate a substantial increase in elution due to 
the presence of the bioactive glass. Although no 
mechanical testing was reported in these two papers, 
it is likely that due to high filler content the strength 
would have decreased very rapidly in solution, 
rendering these composites suitable for bone fillers 
and beads but not for load-bearing applications.  
 Fernandez et al. evaluated the effect of adding 
acrylic-phosphate glasses (P2O5-CaO-Na2O) to PMMA 
bone cement on vancomycin elution.[46] Comparing 
their results to control (0 wt% glass), they found no 
increase in drug release after adding 30% glass by 
weight but did find that 60 wt% and 70 wt% yielded 
substantial increases in drug release. While 
mechanical testing on the composites without 
vancomycin prior to soaking showed little change in 
the strength due to glass incorporation, no data was 
given about strength of the composites after soaking 
and elution. Although unreported, it is likely that the 
high amounts of water soluble acrylic-phosphate led 
to a rapid decrease in the mechanical strength of the 
composite. In our study, we used a relatively low 
amount of glass filler (13-15 wt%) in order to maintain 
compressive strength above 70 MPa while still 
detecting significant increases in vancomycin elution 
above control. 
Study Limitations 
Limitations of our study include those common 
to in vitro elution studies. The nature of in vitro studies 
do not necessarily reflect in vivo or clinical conditions, 
and they do not address the issue of how much 
elution is enough. Elution was carried out in a defined 
volume static solution, which is not necessarily the 
case within the context of the human body. Due to 
differences in hydrostatic pressure against the cement 
surface as well as the solubility of any drug within the 
human body, an absolute comparison to this 
environment with in vitro elution data cannot be 
made. The goal of this study was to directly quantify 
the augmentation of vancomycin elution from PMMA 
due to the addition of a bioactive filler material.  
Conclusions 
Borate bioactive glass addition to commercial 
PMMA bone cement was shown to be an effective 
bioactive filler for the purpose of increasing 
vancomycin from the cement. Even with a modest 
glass filler wt.% relative to other methods, 
vancomycin release is significantly increased both 
during initial burst release and over the subsequent 
lower release period. Importantly, the compressive 
strength of these glass-cement composites are able to 
achieve orthopedic weight-bearing applicability by 
maintaining strength over 70 MPa, even after soaking 
for as long as 8 weeks. 
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